Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,183 total articles
David C. Abrams, a director and ten percent owner of ContextLogic Holdings Inc (NASDAQ: LOGC), filed a Form 4 disclosing a purchase of 1,758,794 shares on February 26, 2026. The shares were acquired at $7.00 each for a total of $12,311,558. After the transaction, Abrams directly and indirectly holds 18,269,534 shares. The purchase was reported seve…
BioMarin Pharmaceutical Inc. EVP and Chief R&D Officer Gregory R. Friberg sold 6,326 shares on February 26, 2026 for a weighted average price of $60.3758, totaling $381,937. The transaction left him with 37,578 shares. Separately, BioMarin reported fourth-quarter 2025 results that missed EPS estimates but topped revenue expectations, prompting a ra…
On February 26, 2026, director Bobbili Raja purchased 1,758,794 shares of ContextLogic Holdings Inc. (NASDAQ: LOGC) at $7.00 per share, a transaction valued at $12,311,558. Following the purchase, Raja's indirect holdings across several investment vehicles total 18,269,534 shares. The stock is trading at $7.98 with a market capitalization of $215 m…
A group of Abrams Capital-affiliated funds acquired 1,758,794 shares of ContextLogic Holdings Inc (LOGC) at $7.00 per share on February 26, 2026, a transaction that totaled $12,311,558. The purchase was reported on an SEC Form 4 and increases the combined Abrams position to 18,269,534 shares. The trade represents roughly 5.7% of ContextLogic's $215…
George Eric Davis, BioMarin Pharmaceutical's Executive Vice President and Chief Legal Officer, sold 26,061 shares of company stock on February 26, 2026, for about $1.6 million. The transaction occurred near the stock's trading level, while the company reported fourth-quarter 2025 results that beat revenue expectations but missed on EPS. Multiple an…
PennyMac Financial Services Chief Legal Officer Derek Stark sold 1,903 shares under a Rule 10b5-1 plan on February 25, 2026, generating about $174,124. The transactions follow tax-withholding of 345 shares tied to vested restricted stock units and come amid a sharp year-to-date share decline and a notable Q4 2025 earnings miss for the firm.
Barry J. Simon, a director at ImmunityBio, sold 75,000 shares of the company on February 24, 2026, under a pre-arranged Rule 10b5-1 plan. The transaction totaled $900,787 at a weighted average price of $12.0105. Separately, ImmunityBio reported ANKTIVA revenue of $113 million for 2025 and expanded commercial partnerships in Europe and the Middle Ea…
Eagle Point Credit Management LLC and Eagle Point DIF GP I LLC, each 10% owners of ACRES Commercial Realty Corp, sold a combined 3,701 shares of the company's 8.625% Series C Preferred Stock between February 24 and February 26, 2026, for a total of $93,489. After the transactions the entities continue to hold substantial positions in both preferred…
Director Marx Felix sold 3,000 shares of Socket Mobile, Inc. (NASDAQ: SCKT) on February 24, 2026, in a transaction that generated $3,000 in proceeds. The sale was disclosed in a Form 4 filing with the SEC. Following the sale, Felix held 8,643 shares. The stock is trading at $0.90, down 11% over the prior week and 20% over the past year, with a mark…
Bloom Energy Chairman and CEO Sridhar KR sold 200,000 Class A shares on February 24, 2026, for about $34 million, at prices between $170.00 and $170.05 per share. The transaction leaves him with 2,189,869 Class A shares. The sale coincides with a stock trading at $168.57 after a 632% gain over the past year and follows a strong Q4 2025 in which Blo…
Director Paul B. Manning bought 550,458 shares of Candel Therapeutics (NASDAQ: CADL) on February 23, 2026, paying $5.45 per share for a total of $2,999,996. The transaction occurred while the stock was trading at $5.15. Manning's direct and indirect holdings, plus recent company filings, outline both insider accumulation and a $100 million public o…
ReposiTrak Chief Executive Officer Randall K. Fields sold 7,500 shares of common stock across February 24 and 25, 2026, through a pre-arranged Rule 10b5-1 plan, generating $62,891 in proceeds. The transactions were reported on a Form 4 filing with the SEC. The company has also declared a quarterly dividend, authorized a new 10b5-1 buyback allocatio…
SkyWest Inc. Chief Commercial Officer Wade J. Steel disposed of 20,629 shares on February 24, 2026, receiving roughly $2.2 million. The transaction occurred at a weighted average price of $106.5281. The company recently reported fourth-quarter 2025 results that topped analyst forecasts, while InvestingPro analysis notes the stock is overvalued vers…
Director Jack Bendheim and BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ: PAHC), sold a combined $1.1 million in Class A common stock between February 24 and February 26, 2026. The disposition comprised 20,120 shares executed under a Rule 10b5-1 trading plan adopted May 30, 2025. The stock is trading near its 52-week high, …
BlackRock Senior Managing Director J. Richard Kushel sold 2,385 shares of BlackRock stock on February 24, 2026, in two transactions that generated $2.58 million in proceeds. The trades were executed at prices between $1,083.05 and $1,084.9101 per share. After the sales, Kushel retains both direct and indirect holdings in the company. The transactio…
Ourania Tatsis, Executive Vice President at Vertex Pharmaceuticals, sold shares under a pre-established Rule 10b5-1 trading plan, disposing of 1,887 shares across two days for roughly $915,724. The trades were filed on a Form 4 with the SEC. Vertex shares trade near their 52-week high even as the company reported a slight EPS miss for Q4 2025 and a…
Amit Sachdev, Vertex Pharmaceuticals' Executive Vice President and Chief Patient & External Affairs Officer, executed two share dispositions across February 24-25, 2026, via a company-approved 10b5-1 trading plan. The transactions reduced his directly held stake while leaving him with substantial direct and indirect holdings. The stock sales oc…
Krystal Biotech director Daniel Janney sold 37,825 shares of common stock on February 24, 2026, generating $10,113,353 in proceeds, and also sold 13,666 shares indirectly owned by Alta Bioequities, L.P. for $6,036,029. Janney simultaneously exercised options to acquire 37,895 shares at $2.46 per share under a Rule 10b5-1 trading plan.
Duncan McKechnie, Vertex Pharmaceuticals' Executive Vice President and Chief Commercial Officer, sold a total of 5,783 shares across February 24-25, 2026, generating roughly $2.81 million in proceeds. The transactions were executed under a 10b5-1 plan and reported via a Form 4 filing. The trade comes while Vertex shares trade near their 52-week hig…
Aftab Dana, Executive Vice President for Research and Development at Exelixis, Inc. (NASDAQ: EXEL), sold 47,918 shares on February 24, 2026, for $44.50 per share, totaling $2,132,351. The transaction occurs while third-party analysis flags the stock as trading below its intrinsic value. Exelixis reported a fourth-quarter 2025 EPS beat but missed re…
Mueller Water Products director Gregg C Sengstack bought 25,000 shares on February 25, 2026, in a transaction valued at $739,415. The purchase occurred as the shares trade close to a 52-week high and follows quarterly results that exceeded analyst forecasts on both earnings per share and revenue. Market valuation metrics from InvestingPro flag the …
Meta Platforms Chief Financial Officer Susan J. Li, via a trust, disposed of 58,478 shares of Class A common stock on February 24, 2026, in transactions totaling roughly $35.3 million. The sales were part of a Rule 10b5-1 plan adopted in November 2025. The filing outlines the trust's remaining indirect holdings and notes related corporateoperationa…
Comfort Systems USA INC (NYSE:FIX) said its president and CEO, Brian E. Lane, sold 9,365 shares on February 25, 2026, in a transaction valued at $13.6 million. The move follows an exceptional stock performance over the past year and a quarter that materially exceeded expectations. The company also reported strong fourth-quarter 2025 results and rec…
Todd M. Cleveland, a director at IES Holdings, Inc. (NASDAQ: IESC), sold 4,896 shares of common stock between February 24 and February 26, 2026, for roughly $2.5 million. The trades came while the stock trades at $515.05, up 177% over the prior year; recent company results showed a revenue beat but an earnings miss for the first quarter of fiscal 2…
iRhythm Holdings' Chief Medical Officer, Minang Turakhia, sold 7,804 shares on February 25, 2026, for roughly $1.05 million, following a week in which the stock fell 11.8% before partial recovery. The filing also shows Turakhia received 15,060 shares the day prior upon vesting of performance RSUs. The company reported robust fourth-quarter results,…
